H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Asensus Surgical (ASXC – Research Report) today and set a price target of $4.00. The company’s shares closed last Wednesday at $0.44, close to its 52-week low of $0.41.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.8% and a 34.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Janux Therapeutics Inc.
Currently, the analyst consensus on Asensus Surgical is a Moderate Buy with an average price target of $4.00.
The company has a one-year high of $3.75 and a one-year low of $0.41. Currently, Asensus Surgical has an average volume of 2.85M.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ASXC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.
Read More on ASXC:
- Analysts’ Opinions Are Mixed on These Technology Stocks: Diodes (DIOD), Qorvo (QRVO) and Ceridian HCM Holding (CDAY)
- Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), United Therapeutics (UTHR) and EyePoint Pharmaceuticals (EYPT)
- ChemoCentryx (CCXI) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)
- Clovis Oncology (CLVS) Receives a Buy from H.C. Wainwright